A Phase 3, Randomized, Clinical Study in HIV-1 Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL.

  • McMahon, James (Primary Chief Investigator (PCI))
  • Roney, Janine J. (Project Manager)

Project: Research

Project Details

Effective start/end date11/06/204/02/22


  • Infectious diseases
  • HIV-1
  • Clinical trial